Abstract
The effects of tertiary amine-containing basic drugs on the enzymes located in the mitochondria and the effect of monoamine oxidase inhibitors (MAOIs) on drug accumulation in lung mitochondria have been studied. Various basic drugs inhibited MAO activity but not other mitochondrial marker enzymes. The potency of MAO inhibition correlated well with their lipid solubility, and the basic drugs inhibited MAO activity dose dependency and competitively. Further, MAO inhibition correlated well with binding affinity to lung mitochondria, and the binding of tertiary amine drugs to lung mitochondria was decreased by treatment with MAOIs. A good correlation was observed between the potency of MAOIs to inhibit the binding of the basic drug to the high-affinity site in mitochondria and the MAO inhibitory activity in mitochondria. These results indicate that mitochondrial MAO is one of the binding sites for tertiary basic drugs in the lung. We think that the action and/or adverse reaction of some drugs may result from inhibition of mitochondrial MAO to metabolize various biogenic amines and that mitochondrial MAO may function as a reservoir for basic drugs.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
K. Okumura, H. Yoshida, and R. Hori. J. Pharmacobio-Dyn. 1:230–237 (1978).
H. Yoshida, K. Okumura, A. Kamiya, and R. Hori. Chem. Pharm. Bull. (Tokyo) 37:450–453 (1989).
H. Yoshida, K. Okumura, and R. Hori. Pharm. Res. 4:50–53 (1987).
R. Hori, K. Okumura, and H. Yoshida. Pharm. Res. 4:142–146 (1987).
K. Okumura, H. Yoshida, A. Kamiya, and R. Hori. Chem. Pharm. Bull. (Tokyo) 37:1109–1111 (1989).
C. Schnaitman, V. G. Erwin, and J. W. Greenawalt. J. Cell. Biol. 32:719–735 (1967).
G. L. Sottocase, B. Kuylenstierna, L. Ernster, and A. Bergstrand. J. Cell. Biol. 32:415–438 (1967).
H. Okamoto and O. Hayaishi. Arch. Biochem. Biophys. 131:603–608 (1969).
J. A. Roth and C. N. Gillis. Biochem. Pharmacol. 23:2537–2545 (1974).
S. Otsuka and Y. Kobayashi. Biochem. Pharmacol. 13:995–1006 (1964).
B. B. Brodie, S. Udenfriend, W. Dill, and G. Downing. J. Biol. Chem. 168:311–318 (1947).
S. J. Cooperstein and A. Lazarow. J. Biol. Chem. 189:665–670 (1951).
S. Wattiaux-De Coninck and R. Wattiaux. Eur. J. Biochem. 19:552–556 (1971).
R. Marco, J. Sebastian, and A. Sols. Biochem. Biophys. Res. Commun. 34:725–730 (1969).
O. H. Lowry, N. J. Rosebrough, A. L. Farr, and J. R. Randall. J. Biol. Chem. 193:265–275 (1951).
H. Lineweaver and D. Burk. J. Am. Chem. Soc. 56:658–667 (1934).
C. Scatchard. Ann. N.Y. Acad. Sci. 51:660–672 (1949).
L. Hellerman and V. G. Erwin. J. Biol. Chem. 243:5234–5243 (1968).
D. Parkinson and B. A. Callingham. J. Pharm. Pharmacol. 32:49–54 (1980).
H. C. Kung and A. G. E. Wilson. Life Sci. 24:425–432 (1979).
M. D. Housley, K. F. Tipton, and M. B. H. Youdin. Life Sci. 19:467–478 (1976).
R. M. Cawthon and X. O. Breakefield. Nature 281:692–694 (1979).
K. F. Tipton, M. D. Houslay, and T. J. Mantle. In. G. E. M. Wolstenholme and J. Knight (eds.), Monoamine Oxidase and Its Inhibition, Elseviers, Amsterdam, 1976, pp. 5–32.
A. J. Richard and L. B. Kier. J. Pharm. Sci. 69:124–126 (1980).
C. J. Fowler and B. C. Callingham. Biochem. Pharmacol. 27:1995–2000 (1978).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Yoshida, H., Kamiya, A., Okumura, K. et al. Contribution of Monoamine Oxidase (MAO) to the Binding of Tertiary Basic Drugs in Lung Mitochondria. Pharm Res 6, 877–882 (1989). https://doi.org/10.1023/A:1015964623098
Issue Date:
DOI: https://doi.org/10.1023/A:1015964623098